PDF herunterladen
Nervenheilkunde 2003; 22(03): 142-145
DOI: 10.1055/s-0038-1624380
Original- und Übersichtsarbeiten/Original and Review Articles
Schattauer GmbH

Sporadische Einschlusskörpermyositis

Ätiologie, Pathogenese und TherapieoptionenSporadic inclusion body myositisetiology, pathogenesis and therapeutic options
M. C. Walter
1   Friedrich-Baur-Institut, Klinikum der Ludwig-Maximilians-Universität
,
H. Lochmüller
1   Friedrich-Baur-Institut, Klinikum der Ludwig-Maximilians-Universität
,
D. Pongratz
1   Friedrich-Baur-Institut, Klinikum der Ludwig-Maximilians-Universität
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. Januar 2018 (online)

    Lizenzen und Reprints

Zusammenfassung

Die sporadische Einschlusskörpermyositis (s-IBM) ist eine chronisch progressive entzündliche Myopathie, die im Wesentlichen jenseits des 50. Lebensjahres auftritt und histologisch durch »rimmed vacuoles« und eosinophile zytoplasmatische Einschlüsse gekennzeichnet ist. Die Ätiologie ist bislang unklar, verschiedene Mechanismen wie Slow-Virus-Infektion, Autoimmunpathogenese, Kernmatrixstörung und Störungen auf mitochondrialer Ebene werden diskutiert. Des Weiteren wird die s-IBM zunehmend in die Nähe von neurodegenerativen Erkrankungen und Prionerkrankungen gerückt. Therapeutische Möglichkeiten sind rar. Immunsuppressiva haben sich als unwirksam erwiesen, eine Stabilisierung des Krankheitsverlaufs ließ sich bislang nur durch hoch dosierte Immunglobulintherapie (IVIG) erreichen. Ein besseres Verständnis der Pathogenese könnte in Zukunft zu verbesserten therapeutischen Optionen führen.

Summary

Sporadic inclusion body myositis (s-IBM) is a chronic progressive inflammatory myopathy which preferentially occurs in older patients. Histologic hallmarks are rimmed vacuoles and eosinophilic cytoplasmatic inclusions. The etiology is still unknown, different pathogenetic mechanisms such as slow-virus-infection, autoimmunpathogenesis, myonuclear alterations and mitochondrial defects were implicated. A relation to neurodegenerative disorders and prion diseases was also suggested. There is a poor if any response to immunosuppressive therapy, stabilization of disease progression was shown by IVIG therapy, only. Future findings in the field of s-IBM pathogenesis may result in better therapeutic options.

Schlüsselwörter

Einschlusskörpermyositis - s-IBM - entzündliche Myopathie - Therapie

Keywords

Inclusion body myositis - s-IBM - inflammatory myopathy - therapy
 

  • Literatur

  • 1 Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. Downregulation of TGF-beta 1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000; 94: 99-104.
    CrossrefGoogle Scholar
  • 2 Argov Z, Tiram E, Eisenberg I, Sadeh M, Seidman CE, Seidman JG, Karpati G, Mitrani-Rosenbaum S. Various types of hereditary inclusion body myopathies map to chromosome 9p1-q1. Annals of Neurology 1997; 41: 548-51.
    CrossrefGoogle Scholar
  • 3 Askanas V, Engel WK, Yang CC, Alvarez RB, Lee VM, Wisniewski T. Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion body myositis and autosomalrecessive inclusion body myopathy. Am J Pathol 1998; 152: 889-95.
    Google Scholar
  • 4 Banwell BL, Engel AG. αB-Crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000; 54: 1033-41.
    CrossrefGoogle Scholar
  • 5 Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 1978; 28: 8-17.
    Google Scholar
  • 6 Chou SM. Inclusion body myositis: a chronic persistent mumps myositis?. Hum Pathol 1986; 17: 765-77.
    CrossrefGoogle Scholar
  • 7 Clark JR, D`Agostino AN, Wilson J, Brooks RR, Cole GC. Autosomal dominant myofibrillar inclusion body myopathy: clinical, histochemical, and ultrastructural characteristics. Neurology 1978; 28: A399.
    Google Scholar
  • 8 Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48: 712-6.
    CrossrefPubMedGoogle Scholar
  • 9 Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T, Barash M, Shemesh M, Sadeh M, Grabov-Nardini G, Shmilevich I, Friedmann A, Karpati G, Bradley WG, Baumbach L, Lancet D, Ben Asher E, Beckmann JS, Argov Z, Mitrani-Rosenbaum S. The UDP-Nacetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nature Genet 2001; 29: 83-7.
    CrossrefGoogle Scholar
  • 10 Garlepp MJ, Laing B, Zilko PJ, Ollier W, Mastaglia FL. HLA associations with inclusion body myositis. Clin Exp Immunol 1994; 98: 40-5.
    Google Scholar
  • 11 Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP. Inclusion body myositis and myopathies. Ann Neurol 1995; 38: 705-13.
    CrossrefPubMedGoogle Scholar
  • 12 Horvath R, Fu K, Johns T, Genge A, Karpati G, Shoubridge EA. Characterization of the mitochondrial DNA abnormalities in the skeletal muscle of patients with inclusion body myositis. J Neuropathol Exp Neurol 1998; 57: 396-403.
    CrossrefGoogle Scholar
  • 13 Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle and Nerve 1998; 21: 115-7.
    CrossrefGoogle Scholar
  • 14 Lampe J, Kitzler H, Walter MC, Lochmüller H, Reichmann H. Methionine homozygosity at prion gene codon 129 may predispose to sporadic inclusion body myositis. Lancet 1999; 353: 465-6.
    CrossrefGoogle Scholar
  • 15 Lindberg C, Persson LI, Björkander J, Olfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994; 89: 123-31.
    Google Scholar
  • 16 Lindberg C, Oldfors A, Trysberg E, Tarkowski A. Anti-thymocyte globuline treatment in inclusion-body myositis. A randomized pilot study. Neuromusc Disord 1999; 09: 476.
    Google Scholar
  • 17 Martinsson T, Oldfors A, Darin N, Berg K, Tajsharghi H, Kyllerman M, Wahlstrom J. Autosomal dominant myopathy: missense mutation (glu-706-to-lys) in the myosin heavy chain IIa gene. Proc Nat Acad Sci 2000; 97: 14614-9.
    CrossrefGoogle Scholar
  • 18 Martinsson T, Darin N, Kyllerman M, Oldfors A, Hallberg B, Wahlström J. Dominant hereditary inclusion body myopathy gene (IBM3) maps to chromosome region 17p13.1. Am J Hum Genet 1999; 64: 1420-6.
    CrossrefGoogle Scholar
  • 19 Megens de Letter MA, Visser LH, van Doorn PA, Savelkoul HF. Cytokines in the muscle tissue of idiopathic inflammatory myopathies: implications for immunopathogenesis and therapy. Eur Cytokine Netw 1999; 10: 471-8.
    Google Scholar
  • 20 Nakayama T, Horiuchi E, Watanabe T, Murayama S, Nakase H. A case of inclusion body myositis with benign monoclonal gammopathy successfully responding to repeated immunoabsorption. J Neurol Neurosurg Psychiatry 2000; 68: 230-3.
    CrossrefGoogle Scholar
  • 21 Nalbantoglu J, Karpati G, Carpenter S. Conspicuous accumulation of a single-stranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol 1994; 144: 874-82.
    Google Scholar
  • 22 Naumann M, Reichmann H, Goebel HH, Moll C, Toyka KV. Glucocorticoid-sensitive hereditary inclusion body myositis. J Neurol 1996; 1243: 126-30.
    Google Scholar
  • 23 Oldfors A, Larsson NG, Lindberg C, Holme E. Mitochondrial DNA deletions in inclusion body myositis. Brain 1993; 116: 325-36.
    CrossrefGoogle Scholar
  • 24 Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002; 58: 1081-7.
    CrossrefGoogle Scholar
  • 25 Spector SA, Lemmer JT, Koffman BM, Fleisher TA, Feuerstein IM, Hurley BF, Dalakas MC. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 1997; 20: 1242-8.
    CrossrefPubMedGoogle Scholar
  • 26 The Muscle Study Group. Randomized pilot trial of βINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001; 57: 1566-70.
    CrossrefGoogle Scholar
  • 27 Walter MC, Lochmüller H, Toepfer M, Schlotter B, Reilich P, Schröder M, Müller-Felber W, Pongratz D. High-dose immunoglobulin therapy (IVIG) in inclusion body myositis (IBM): A double-blind, placebo-controlled study. J Neurol 2000; 247: 22-8.
    CrossrefPubMedGoogle Scholar
  • 28 Yang CC, Askanas V, Engel WK, Alvarez RB. Immunolocalization of transcription factor NF-κB in inclusion body myositis muscle and at normal human neuromuscular junctions. Neuroscience Letters 1998; 254: 77-80.
    CrossrefGoogle Scholar